Teva says U.S. approves generic form of Accupril

NEW YORK, Aug 27 (Reuters) - Teva Pharmaceutical Industries Ltd. (TEVA.O) said on Monday that U.S. regulators had approved its generic form of Pfizer Inc's (PFE.N) Accupril treatment for high blood pressure.

The Israel-based drugmaker said all forms of Accupril, including generic products already sold under its chemical name quinapril, had U.S. sales of $150 million during the 12 months ending June 30.

((Reporting by Ransdell Pierson, editing by Jeffrey Benkoe; Reuters Messaging: ransdell.pierson.reuters.com@reuters.net; 646-223-6034; ransdell.pierson@reuters.com)) Keywords: TEVA ACCUPRIL/

(C) Reuters 2007. All rights reserved. Republication or redistribution ofReuters content, including by caching, framing or similar means, is expresslyprohibited without the prior written consent of Reuters. Reuters and the Reuterssphere logo are registered trademarks and trademarks of the Reuters group ofcompanies around the world.nWNAS2927